49 Spam-Free Article(s) Found
Article Searches
3 Reasons Pharma Stocks Are a Buy Right Now https://www.fool.com/investing/2020/03/25/3-reasons-pharma-stocks-are-a-buy-right-now.aspx?source=iedfolrf0000001 Mar 25, 2020 - The coronavirus outbreak has made shares of top drugmakers more attractive than they've been in a quite a while.
Eli Lilly Licenses Immunology Drugs for Up to $880 Million https://www.fool.com/investing/2020/03/31/eli-lilly-licenses-immunology-drugs-for-up-to-880.aspx?source=iedfolrf0000001 Mar 31, 2020 - The pharma giant will develop and market up to four drugs from the pipeline of privately-held Sitryx.
Eli Lilly Starts Clinical Trial for Potential COVID-19 Treatment https://www.fool.com/investing/2020/04/11/eli-lilly-starts-clinical-trial-for-potential-covi.aspx?source=iedfolrf0000001 Apr 11, 2020 - The pharma company believes that its rheumatoid arthritis treatment Olumiant could be effective at treating COVID-19 patients.
Eli Lilly and Company (LLY) CEO Dave Ricks on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4339567-eli-lilly-and-company-lly-ceo-dave-ricks-on-q1-2020-results-earnings-call-transcript?source=feed_sector_healthcare Apr 23, 2020 - Eli Lilly and Company (NYSE:LLY) Q1 2020 Results Conference Call April 23, 2020 09:00 AM ET Company Participants Kevin Hern - VP, IR Dave Ricks - Chairman and CEO Josh Smiley - CFO Dr. Dan Skovronsky
Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks? https://www.fool.com/investing/2020/04/01/do-clinical-trial-delays-mean-trouble-for-pharmace.aspx?source=iedfolrf0000001 Apr 01, 2020 - Postponed clinical trials might mean a longer time-to-market for certain drugs.
Agios' IND for PKR Activator AG-946 Gets FDA Clearance http://www.zacks.com/stock/news/832392/agios-ind-for-pkr-activator-ag-946-gets-fda-clearance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-832392 Mar 24, 2020 - The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants http://www.zacks.com/stock/news/834155/pfizers-eczema-drug-eucrisa-gets-fda-approval-for-infants?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-834155 Mar 25, 2020 - Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.
Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus http://www.zacks.com/stock/news/847731/buy-this-high-yield-large-cap-pharma-stock-for-income-amid-coronavirus?cid=CS-ZC-FT-video_blog-847731 Mar 31, 2020 - AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty...
3 Drugmakers Still Worth Betting on Amid Coronavirus Woes http://www.zacks.com/stock/news/849056/3-drugmakers-still-worth-betting-on-amid-coronavirus-woes?cid=CS-ZC-FT-analyst_blog|investment_ideas-849056 Apr 01, 2020 - Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
3 Stocks Immune to the Coronavirus Downturn to Buy Right Now http://www.zacks.com/stock/news/857564/3-stocks-immune-to-the-coronavirus-downturn-to-buy-right-now?cid=CS-ZC-FT-zacks_friday_finish_line-857564 Apr 06, 2020 - Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...

Pages: 12345

Page 1>